ATE216234T1 - Zusammensetzungen aus aminosäure zur behandlung von infektionen - Google Patents

Zusammensetzungen aus aminosäure zur behandlung von infektionen

Info

Publication number
ATE216234T1
ATE216234T1 AT94402420T AT94402420T ATE216234T1 AT E216234 T1 ATE216234 T1 AT E216234T1 AT 94402420 T AT94402420 T AT 94402420T AT 94402420 T AT94402420 T AT 94402420T AT E216234 T1 ATE216234 T1 AT E216234T1
Authority
AT
Austria
Prior art keywords
cysteine
amino acid
proportion
acid compositions
treating infections
Prior art date
Application number
AT94402420T
Other languages
English (en)
Inventor
Maurice Arnal
Francis Rose
Denis Breuille
Christiane Obled
Original Assignee
Nestle Sa
Agronomique Inst Nat Rech
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9452315&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE216234(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Nestle Sa, Agronomique Inst Nat Rech filed Critical Nestle Sa
Application granted granted Critical
Publication of ATE216234T1 publication Critical patent/ATE216234T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/01—Hydrolysed proteins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
AT94402420T 1993-10-28 1994-10-27 Zusammensetzungen aus aminosäure zur behandlung von infektionen ATE216234T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9312884A FR2711529B1 (fr) 1993-10-28 1993-10-28 Composition à base d'acides aminés destinée au traitement d'une infection ou d'une agression engendrant une réaction inflammatoire, chez les animaux et chez l'homme.

Publications (1)

Publication Number Publication Date
ATE216234T1 true ATE216234T1 (de) 2002-05-15

Family

ID=9452315

Family Applications (1)

Application Number Title Priority Date Filing Date
AT94402420T ATE216234T1 (de) 1993-10-28 1994-10-27 Zusammensetzungen aus aminosäure zur behandlung von infektionen

Country Status (9)

Country Link
EP (1) EP0655244B2 (de)
KR (1) KR950010884A (de)
AT (1) ATE216234T1 (de)
CA (1) CA2134380C (de)
DE (1) DE69430416T3 (de)
DK (1) DK0655244T5 (de)
ES (1) ES2171439T5 (de)
FR (1) FR2711529B1 (de)
PT (1) PT655244E (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999038507A1 (en) * 1998-01-30 1999-08-05 David George Le Couteur Reversal and prevention of clinically significant aspects of aging through oral use of hepatic artery vasodilator and other agents which increase hepatic oxygenation
ES2261383T5 (es) * 2000-02-04 2010-06-18 Societe Des Produits Nestle S.A. Un metodo para mantener o mejorar la sintesis de mucinas.
EP1302115A1 (de) * 2001-10-16 2003-04-16 Societe Des Produits Nestle S.A. Verwendung von Cystathionin
US20080032915A1 (en) * 2004-02-12 2008-02-07 Campina Nederland Holding B.V. Cysteine Rich Peptides for Improving Thiol Homeostasis
WO2006134135A2 (en) * 2005-06-14 2006-12-21 Nestec S.A. Nutritional method for elderly people
DE102006018293A1 (de) * 2006-04-20 2007-10-25 Fresenius Kabi Deutschland Gmbh Pädiatrische Aminosäurelösung zur parenteralen Ernäherung
EP2165713B1 (de) 2008-09-19 2012-11-14 Nestec S.A. Molke und Verbesserung der Thymusfunktion
WO2011021926A1 (en) * 2009-08-21 2011-02-24 N.V. Nutricia Regulating the amino acid pool used for the acute-phase protein synthesis
EP2444083A1 (de) 2010-10-21 2012-04-25 Nestec S.A. Cystein- und Nahrungsmittelaufnahme
WO2024122796A1 (ko) * 2022-12-05 2024-06-13 의료법인 성광의료재단 아스파르트산을 유효성분으로 포함하는 패혈증의 예방 또는 치료용 약학적 조성물

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2531204C2 (de) * 1975-07-12 1987-01-22 Fresenius AG, 6380 Bad Homburg L-Aminosäuregemische für die parenterale oder orale Ernährung
DE2946563C2 (de) * 1979-11-17 1987-04-30 B. Braun Melsungen Ag, 3508 Melsungen Aminosäurelösung zur parenteralen Infusion
DE3026368A1 (de) * 1980-07-11 1982-02-18 Lentia GmbH Chem. u. pharm. Erzeugnisse - Industriebedarf, 8000 München Naehrloesung fuer die vollstaendige parenterale ernaehrung und fuer gesteigerte energieproduktion
US4604286A (en) * 1984-09-17 1986-08-05 Daigo Nutritive Chemicals, Ltd. Infusion solution for parenteral nutrition
ES2039402T3 (es) * 1986-10-24 1993-10-01 Pfrimmer Kabi Gmbh & Co. Kg Empleo de peptidos n,n'-bis-l-aminoacido-l-cistina en preparados de aminoacidos para alimentacion oral y parenteral.
SE8704217D0 (sv) * 1987-10-29 1987-10-29 Vinnars Erik Ab Aminosyrakomposition for parenteral neringstillforsel
US5224409A (en) † 1991-03-19 1993-07-06 Ashlock Company Apparatus for producing helical slices
US5214062A (en) † 1992-04-08 1993-05-25 Clintec Nutrition Co. Method and composition for treating immune disorders, inflammation and chronic infections
AU6060694A (en) † 1993-05-10 1994-11-17 Transcend Therapeutics, Inc Method for treating acquired immune deficiency syndrome

Also Published As

Publication number Publication date
ES2171439T5 (es) 2008-12-01
DK0655244T5 (da) 2008-10-13
EP0655244B1 (de) 2002-04-17
DK0655244T3 (da) 2002-08-05
FR2711529B1 (fr) 1996-07-05
DE69430416T3 (de) 2009-01-22
PT655244E (pt) 2002-08-30
EP0655244B2 (de) 2008-06-11
KR950010884A (ko) 1995-05-15
ES2171439T3 (es) 2002-09-16
DE69430416T2 (de) 2002-12-05
DE69430416D1 (de) 2002-05-23
EP0655244A1 (de) 1995-05-31
CA2134380C (en) 2010-06-22
CA2134380A1 (en) 1995-04-29
FR2711529A1 (fr) 1995-05-05

Similar Documents

Publication Publication Date Title
DE69305105D1 (de) Zusammensetzungen zur oralen Nahrungsmittelaufnahme mit verbessertem Geschmack
DE69429297D1 (de) Zusammensetzung zur Behandlung von Patienten mit Lebererkrankungen
EP0966297A4 (de) Verfahren zur regulation gastrointestinaler beweglichkeit
AU6819294A (en) Oral drug delivery compositions and methods
FI941500A0 (fi) Hormonianalogit joissa on moninkertaisia CTP-lisäkkeitä
ATE165100T1 (de) Peptide mit endothelin antagonistischer aktivität, deren herstellung und pharmazeutische zusammensetzungen
ATE187740T1 (de) Modifizierte proteine und peptide enthaltende pharmazeutische mittel
NO20023224L (no) DNA som koder for et biologisk aktivt fragment av baktericid/permeabilitetsökende protein, fremgangsmåte forfremstilling av dette, samt farmasöytisk preparat inneholdendedette
ATE213499T1 (de) Peptidanaloge des menschlichen, basischen myelinproteins mit substitution an position 91 zur behandlung der multiplen sklerose
DE59810596D1 (de) Humanes, rekombinantes interferon-beta mit verbesserter löslichkeit
DE69430416D1 (de) Zusammensetzungen aus Aminosäure zur Behandlung von Infektionen
AU7683296A (en) Peptide conjugates derived from thymic hormones, their use as medicament and compositions containing them
NO863398L (no) Smaksmaskerende preparater.
ATE69164T1 (de) Arzneimittel zur behandlung von uraemie.
WO2002058589A3 (en) Agents and methods for promoting bone growth
ATE3416T1 (de) Pharmakologisch aktive peptide und diese enthaltende arzneimittel.
ATE272399T1 (de) Zusammensetzungen aus aminosäuren zur behandlung von herzinsuffizienz
BG103905A (en) New bpc peptide salts with organoprotective activity, method for their preparation and application in medicine
DE60001489D1 (de) Pharmazeutische zubereitung für die intravenöse oder intramuskuläre verabreichung von octreotid
FI942938A0 (fi) Soijaproteiini tai -hydrolysaatit farmaseuttisissa koostumuksissa bioaktiivisten peptidien suojana entsymaattista inaktivoitumista vastaan
WO1998001474A3 (en) Derivatives of somatostatin, amino acids or oligopeptides and their combination useful for promoting body growth
DE60040856D1 (de) Lactalbumin zur kurativen Behandlung von Magengeschwüren

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties